A Boehringer Ingelheim drug in growth for weight reduction now has information from a separate mid-stage medical trial exhibiting dramatic reductions in a number of measures of a fatty liver illness whose critical issues may result in the necessity for a liver transplant. In preliminary Section 2 medical trial outcomes introduced Monday, 48 weeks of therapy with the experimental drug, […]